immunotherapy Archives - PharmaDeviceNews

Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing

T-CURX and Pantherna are combining CAR-T, mRNA and LNP platforms. Europe’s in vivo cell therapy race just became more serious.

Amgen’s Imdylltra has European approval in relapsed small cell lung cancer. Survival data now face reimbursement and adoption tests.

Find out how BeOne’s HERIZON-GEA data could reshape HER2-positive gastroesophageal cancer treatment after ASCO 2026.

Find out how Brenus Pharma’s STC-1010 FDA IND acceptance could reshape MSS colorectal cancer immunotherapy development.

Could AstraZeneca’s latest ASCO 2026 cancer data reshape future treatment sequencing in liver and breast oncology? Read the full analysis.

MRD testing just crossed into treatment selection. Natera’s Signatera FDA win could reshape adjuvant bladder cancer care.

Stomach cancer care gains immunotherapy, but NHS adoption now depends on surgery timing, toxicity management and recurrence data.

Can-Fite BioPharma Ltd. advances Namodenoson into Phase 2b pancreatic cancer testing. Discover what this means for immunotherapy economics.

Discover how Syncromune Inc.’s SYNC-T data could reshape combination immunotherapy. Find out what this means for cancer treatment innovation.

Tempest Therapeutics, Inc. advances TPST-2003 CAR-T data. Discover how dual-targeting could impact multiple myeloma treatment durability.